Subscribe free

HPB & Spleen ·

Consensus on HCC Trial Designs for Systemic Therapies

A panel of experts reached consensus on guidelines for clinical trials evaluating systemic therapies in hepatocellular carcinoma (HCC) patients undergoing surgical or locoregional treatment, emphasizing patient selection and outcome measures.

  • Nine consensus statements were established for both neoadjuvant and combination therapy trials, focusing on high-risk patients and clinically relevant endpoints.
  • For neoadjuvant therapy, the primary outcome should be 2-year event-free survival; for combination therapy, use progression-free survival and overall survival.

These guidelines could influence trial designs, ensuring rigorous evaluation of systemic therapies in surgical HCC management.

Journal Article by Yarchoan M, Llovet JM (…) Singal AG et 24 al. in Gut

© Author(s) (or their employer(s)) 2026. No commercial re-use. See rights and permissions. Published by BMJ Group.

read the whole article in Gut

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in HPB & Spleen.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in HPB & Spleen

The latest stitches

All papers in HPB & Spleen →